Showing results (211-220 of 247) with videos related to

Sort By:
Pageof 25
Biorxiv : the Preprint Server for Biology|February 19, 2024
Far-red and sensitive sensor for monitoring real time H2O2 dynamics with subcellular resolution and in multi-parametric imaging applicationsJustin Daho Lee, Amanda Nguyen, Zheyu Ruby Jin, et al.
JACC. Heart Failure|August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection FractionSara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
Critical Care (London, England)|January 4, 2022
Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trialMario G Santamarina, Ignacio Beddings, Felipe Martinez Lomakin, et al.
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|May 22, 2023
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trialsAnkeet S Bhatt, Mikhail N Kosiborod, Muthiah Vaduganathan, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
Social Exclusion Amplifies Behavioral Responses to Physical Pain via Insular NeuromodulationCaroline Jia, Andrea Tran, Faith Aloboudi, et al.
European Heart Journal|May 23, 2023
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialSafia Chatur, Muthiah Vaduganathan, Brian Claggett, et al.
JACC. Heart Failure|July 1, 2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF TrialScott D Solomon, Adel R Rizkala, Jianjian Gong, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 12, 2024
Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1Johanna R Abend, Atul Sathe, Matthias B Wrobel, et al.
Pageof 25